指南与共识前列腺癌

靶向治疗:前列腺局灶治疗后磁共振成像评估前列腺的跨大西洋建议:系统综述与国际共识推荐

The Transatlantic Recommendations for Prostate Gland Evaluation with Magnetic Resonance Imaging After Focal Therapy (TARGET): A Systematic Review and International Consensus Recommendations.
指南 / 共识 · Eur Urol · 2024-03-21

该系统综述于2022年7月检索,纳入73项研究,并由欧洲和北美23名专家经两轮共识会议(2023年1月)制定TARGET推荐。关键推荐包括局灶治疗后12个月采用符合PI-RADS v2.1标准的多参数MRI方案进行常规MRI检查,避免使用PI-RADS评分评估消融区内复发,并提出替代5点评分系统。

要点

  • 推荐局灶治疗后12个月采用符合PI-RADS v2.1标准的多参数MRI方案进行常规检查。
  • 应避免使用PI-RADS分类评分评估消融区内复发。
  • 提出包含DCE主要序列及DWI与T2WI联合次要序列的替代5点评分系统。

核心结论

  • TARGET共识推荐可能改善前列腺癌局灶治疗后MRI的采集、判读和报告,并为研究报道提供最低标准。

研究设计与样本

  • 系统综述于2022年7月进行,纳入73项研究,随后进行两轮共识练习,2023年1月举行共识会议,由来自欧洲和北美的23名专家(涵盖泌尿外科、放射科和病理科,具有八种局灶治疗模式经验)对329条陈述进行评分,采用RAND公司/加州大学洛杉矶分校方法学制定推荐。

主要发现

  • 所有20项(100%)报告可疑影像特征的研究均提及局灶性对比增强为癌症复发的可疑征象。
  • 在31项报告MRI评估标准的研究中,PI-RADS评分是最常用的方案(20项研究;65%),其次是5点Likert评分(6项研究;19%)。
  • 共识练习中,对评分陈述达成同意或不同意的比例从第一轮的295条中227条(76.9%)增加至第二轮的329条中270条(82.1%)。

关键数值与推荐

  • 推荐在12个月时进行常规MRI检查,使用符合PI-RADS版本2.1标准的多参数方案。
  • 应避免使用PI-RADS分类评分评估消融区内复发。
  • 提出替代5点评分系统,包括主要动态对比增强(DCE)序列和联合次要扩散加权成像(DWI)与T2加权序列。
  • 对于DCE序列,局灶结节状强早期增强是最可疑的影像学发现。
  • 提出结构化的最低报告数据集以及局灶治疗后MRI研究的最低报告标准。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Magnetic resonance imaging (MRI) can detect recurrences after focal therapy for prostate cancer but there is no robust guidance regarding its use. Our objective was to produce consensus recommendations on MRI acquisition, interpretation, and reporting after focal therapy. METHODS: A systematic review was performed in July 2022 to develop consensus statements. A two-round consensus exercise was then performed, with a consensus meeting in January 2023, during which 329 statements were scored by 23 panellists from Europe and North America spanning urology, radiology, and pathology with experience across eight focal therapy modalities. Using RAND Corporation/University of California-Los Angeles methodology, the Transatlantic Recommendations for Prostate Gland Evaluation with MRI after Focal Therapy (TARGET) were based on consensus for statements scored with agreement or disagreement. KEY FINDINGS AND LIMITATIONS: In total, 73 studies were included in the review. All 20 studies (100%) reporting suspicious imaging features cited focal contrast enhancement as suspicious for cancer recurrence. Of 31 studies reporting MRI assessment criteria, the Prostate Imaging-Reporting and Data System (PI-RADS) score was the scheme used most often (20 studies; 65%), followed by a 5-point Likert score (six studies; 19%). For the consensus exercise, consensus for statements scored with agreement or disagreement increased from 227 of 295 statements (76.9%) in round one to 270 of 329 statements (82.1%) in round two. Key recommendations include performing routine MRI at 12 mo using a multiparametric protocol compliant with PI-RADS version 2.1 standards. PI-RADS category scores for assessing recurrence within the ablation zone should be avoided. An alternative 5-point scoring system is presented that includes a major dynamic contrast enhancement (DCE) sequence and joint minor diffusion-weighted imaging and T2-weighted sequences. For the DCE sequence, focal nodular strong early enhancement was the most suspicious imaging finding. A structured minimum reporting data set and minimum reporting standards for studies detailing MRI data after focal therapy are presented. CONCLUSIONS AND CLINICAL IMPLICATIONS: The TARGET consensus recommendations may improve MRI acquisition, interpretation, and reporting after focal therapy for prostate cancer and provide minimum standards for study reporting. PATIENT SUMMARY: Magnetic resonance imaging (MRI) scans can detect recurrent of prostate cancer after focal treatments, but there is a lack of guidance on MRI use for this purpose. We report new expert recommendations that may improve practice.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Light A, Mayor N, Cullen E, et al. The Transatlantic Recommendations for Prostate Gland Evaluation with Magnetic Resonance Imaging After Focal Therapy (TARGET): A Systematic Review and International Consensus Recommendations. Eur Urol. 2024. PMID: 38519280. doi:10.1016/j.eururo.2024.02.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。